Company intelligence / Profile preview

Novadip Biosciences

Mont-Saint‑Guibert, Belgium

Ownership: Private
Employees: ~45
Development stage: Phase 2

Overview

Novadip has demonstrated strong clinical proof-of-concept for its autologous therapy NVD003 in congenital pseudarthrosis of the tibia and adult nonunion fractures. Its allogeneic product NVDX3 has shown high rates of durable bone union with no related adverse events at one year post-treatment. Both products are advancing toward pivotal trials.

Therapeutic areas: OtherRare DiseasesRheumatology
Modalities: Autologous cell-based therapies (using adipose-derived stem cells)Allogeneic cell-based therapies (off-the-shelf bone grafts)Exosome/miRNA-based therapeutics (early stage)Tissue engineering/scaffold-free constructs
Industry: Biotech

Drug pipeline

4 assets

NVD-003

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Novadip Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novadip Biosciences.

Explore the full profile